Free shipping for any 2 packs purchased

latest news about cgm devices

Latest news & updates from CGMs World – September news

Hello, patchers!

As the prevalence of Type 1 diabetes is increasing day by day, so is the usage of CGMs too. This is because CGMs improve your glycemic control, provide a fast and proactive response by checking your sugar levels every few minutes. Undoubtedly, they are easy, flexible, and effective for anyone regardless of age differences. Let’s discuss some of the fascinating realities about CGMs and type 1 diabetes that you might have never heard about.

A recent study showed that a group of U.S. researchers have developed an A.I. (artificial intelligence) based highly specialized artificial pancreatic system for children (6 years and above) that has advanced level CGMs that also deliver insulin when required. The scientists also believe that this technology can be a pivot in the diabatic healthcare industry by not only maintaining glycemic control but also preventing severe complications associated with the disease such as hypocalcemia, seizures etc. Besides that, this can be a huge relaxation for caregivers and parents believing that their children are safer, and kids can also enjoy being kids. 

Based on the CGMs’ successful outcomes and increasing needs, Variety-A children charity organization has decided to provide direct funding to help children in B.C. and the Yukon for continuous glucose monitors. To signify this, Dr Tom Elliott, BC Diabetes Medical Director says that it’s a game-changing basic human right medical device facilitating kids, parents and healthcare providers, as it warns parents and caregivers when the child’s sugars are going down at any time so that the timely treatment can be done. 

In addition, the most commonly used CGM patches these days are Freestyle Libre, Dexcom G6, and Medtronic Guardian. Let’s discuss some of the most compelling facts and news regarding these widely used patches.

Freestyle Libre

One of the most exciting news aired last week was that Abbott’s Libre Sense Glucose Sport Biosensor, with CE Mark (Conformité Européenne), is an over-the-counter-product that aids athletes (16 years and above) in monitoring their sugar levels via mobile app. This tracking and monitoring glucose levels allow them to replenish their glucose reserves if lowered down, whether during training or competitions. Jared Watkin, senior vice president, Diabetes Care, Abbott believes that this breakthrough medical technology has all the potential to empower athletes to help them achieve their athletic performance goals and let them know what is happening in their body in order to opt for timely disease management for health and professional improvement.

Three Australians, Tyson, Gavin, and Leanne, while describing their diabatic technology journey said that Freestyle libre has made their life easier and more relaxed than ever before. This has not only improved the pain of recurrent needle sticks but also reduced the fear and anxiety related to the potential adversities of the disease.

Apart from this, Abbott has received C.E. mark for freestyle Libre 3 continuous glucose monitor, that is claimed to be the thinnest and smallest continuous glucose monitor in the world, at the size of two stacked U.S. pennies. However, Abbot aims to keep it affordable by not changing its price to maximize accessibility across the world.

Dexcom G6 and friends 

Being the leader in real-time continuous glucose monitoring industry, Dexcom has made its G6 system available to assist healthcare professionals to remotely monitor the glucose levels of their patients admitted in the hospital due to COVID 19. Due to the pressing need of limiting patient-staff contact in healthcare settings during the pandemic, the company has taken this remarkable step in preventing COVID transmission and best possible health outcome for these patients.

While Abbot has targeted athletes in sugar maintenance, Dexcom is eyeing hospitals and healthcare settings by launching a registry to monitor their diabetic patients’ outcomes in U.S. hospitals. Matt Dolan, head of new markets at Dexcom, in an interview said that their goal is to develop a permanent solution for the problem.

Likewise, the economic analysis provided to the National Institute for Health and Care Excellence will support NHS-England in providing equal access to rt-CGM to the T1D patients, thus removing the unnecessary and inconsistent postcode prescribing.

Medtronic Guardian

Medtronic, as principally working for insulin technology, announced that they aim to develop Smartpen, that is an integrated system of CGM and insulin pen (Inpen). “This is an unprecedented approach”, says Mike Hill, vice president and general manager, Multiple Daily Injection Solutions, at Medtronic. He continues that “This will help the users to track their glucose levels, monitor active insulin levels, recommend insulin doses, give reminders for insulin doses and alarms in case of hypoglycemia.

All these advances in the diabatic technology show how adaptive these companies are in bringing the impactful transformation in our diabatic healthcare industry.

This brings us to an end, I hope this post has provided you with some valuable, innovative and compelling factual information regarding CGMs. Let us know what you have found interesting. Share your comments, feedback and stories with us and let us know how we can improve.  

Have a lovely day!

NJaP Team